ArticleBiomolecules2019
Lignin and Cellulose Blends as Pharmaceutical Excipient for Tablet Manufacturing via Direct Compression.
Article in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 62 citations in OpenAlex.
- Polysaccharides and carbohydrate polymers: innovations from nature to industry.Journal of the science of food and agriculture · 2026Review
- Reservoir-Type Subcutaneous Implantable Devices Containing Porous Rate Controlling Membranes for Sustained Delivery of Risperidone.Advanced healthcare materials · 2025Article
- The Evaluation of Cellulose from Agricultural Waste as a Polymer for the Controlled Release of Ibuprofen Through the Formulation of Multilayer Tablets.Bioengineering (Basel, Switzerland) · 2025Article
- A comprehensive review of unlocking the potential of lignin-derived biomaterials: from lignin structure to biomedical application.Journal of nanobiotechnology · 2025Review
- Comparative Effect of Antioxidant and Antibacterial Potential of Zinc Oxide Nanoparticles from Aqueous Extract ofMaterials (Basel, Switzerland) · 2024Article
- Pharmaceutical applications of lignin-derived chemicals and lignin-based materials: linking lignin source and processing with clinical indication.Biomass conversion and biorefinery · 2024Review
- Enhanced Production of Active Photosynthetic and Biochemical Molecules inMolecules (Basel, Switzerland) · 2023Article
- Porphyrin Photosensitizers Grafted in Cellulose Supports: A Review.International journal of molecular sciences · 2023Review
- Article
- Interface Strength and Fiber Content Influence on Corn Stover Fibers Reinforced Bio-Polyethylene Composites Stiffness.Polymers · 2021Article
- Morphological and Wettability Properties of Thin Coating Films Produced from Technical Lignins.Langmuir : the ACS journal of surfaces and colloids · 2020Article
- A Comparison between Several Response Surface Methodology Designs and a Neural Network Model to Optimise the Oxidation Conditions of a Lignocellulosic Blend.Biomolecules · 2020Article
- Lignin/poly(butylene succinate) composites with antioxidant and antibacterial properties for potential biomedical applications.International journal of biological macromolecules · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extensive efforts are being made to find alternative uses for lignin (LIG). In the present work the use of this biopolymer as excipient to prepare tablets was studied. For this purpose, LIG was combined with microcrystalline cellulose (MCC) and used as excipients to prepare directly compressed tablets containing a model drug, tetracycline (TC). The excipients contained different concentrations of LIG: 100%, 75%, 50%, 25% and 0% (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.